$220 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 42 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EOCWU | ELLIOTT OPPORTUNITY II CORP | $20,020,000 | -1.1% | 2,000,000 | 0.0% | 9.09% | -21.4% | |
| TSHA | TAYSHA GENE THERAPIES INC | $13,363,000 | -37.4% | 1,147,040 | 0.0% | 6.07% | -50.3% | |
| CDAK | CODIAK BIOSCIENCES INC | $9,437,000 | -31.8% | 847,108 | 0.0% | 4.28% | -45.8% | |
| IMTX | IMMATICS NV | $9,373,000 | +3.4% | 697,431 | 0.0% | 4.26% | -17.9% | |
| VT | VANGUARD TOT WORLD STK ETFetfs | $9,061,000 | +5.5% | 84,339 | 0.0% | 4.12% | -16.1% | |
| TXN | TEXAS INSTRUMENTS INC | $6,031,000 | -2.0% | 32,000 | 0.0% | 2.74% | -22.1% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $1,167,000 | -40.2% | 245,678 | 0.0% | 0.53% | -52.5% | |
| PLXP | PLX PHARMA INC | $502,000 | -58.5% | 62,673 | 0.0% | 0.23% | -67.0% | |
| TFFP | TFF PHARMACEUTICALS INC | $196,000 | +15.3% | 22,066 | 0.0% | 0.09% | -8.2% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $141,000 | -18.0% | 35,714 | 0.0% | 0.06% | -34.7% | |
| APEN | APOLLO ENDOSURGERY INC | $132,000 | -6.4% | 15,601 | 0.0% | 0.06% | -25.9% | |
| POR | PORTLAND GENERAL ELECTRIC CO | $6,000 | 0.0% | 118 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4/A | 2024-05-14 |
| 4 | 2024-05-01 |
| 3 | 2024-04-30 |
| 13F-HR | 2024-04-30 |
| 144 | 2024-04-29 |
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-04 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.